Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1/2 5Phase 1 5Phase EARLY_PHASE1 3Phase 3 1

Status

Completed 54Active not recruiting 26Terminated 25Recruiting 19Withdrawn 5Unknown 3Not yet recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × atezolizumab × Clear all
NCT06416436 2025-06-29

Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients

University of Kansas Medical Center

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT06719973 2025-06-17

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

EMD Serono

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumors

NCT05510427 2023-08-15

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Gastrointestinal

Liver Neoplasms, Cholangiocarcinoma

NCT03498222 2020-02-25

iTRAP

Queen Mary University of London

Phase 1 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03369964 2018-04-05

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Hoffmann-La Roche

Phase 1 Withdrawn
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡